As a part of its first phase to broaden access to its medications, the French pharmaceutical company Sanofi S.A. will make 30 of its therapies, including insulin, accessible on a not-for-profit model in 40 lower-income nations.

The procedures will be offered under the new Impact brand, which is a part of Sanofi's global health division that was formed last year and is separate from the company's commercial operations. Sanofi said the proposal also involves the USD 25 million Impact fund, which would help emerging healthcare enterprises in the area and offer training on medication usage.

The head of the global health unit Jon Fairest mentioned that investing in innovation, in the ecosystem, is a new thing. There's plenty of noise right now from different corporations moving into this field.

Additionally, the World Health Organization has listed Sanofi’s therapies as important medications, and the U.N. agency has highlighted insulin as a life-saving drug for diabetics that is difficult to get in many lower-income nations where the disease burden is rising.

The list also contains non-patent remedies for diseases like tuberculosis, malaria, hypertension, and cancer. Sanofi did not go into specifics about how much the new approach would reduce drug pricing.

Notably, from Niger through Zimbabwe, most of the concerned nations are in Africa. The effort includes several Asian nations including Cambodia and Myanmar as well as conflict-affected nations like Syria.

Sanofi Global Health was founded in 2021 to create a nonprofit division within Sanofi to improve healthcare accessibility by expanding the distribution of pharmaceuticals. In low-income nations, the unit has also overseen establishing and sustaining local healthcare systems.

Sanofi's Chief Executive Paul Hudson believes that they have a responsibility to create an impact on the health of people that need it and recognize the ability the company possesses with the ambition to bring about permanent change.

Source Credits:

https://www.thepharmaletter.com/article/new-sanofi-brand-designed-to-broaden-access-to-medicines